GEN Exclusives

More »

GEN News Highlights

More »
Jun 9, 2008

Cobrabio to Manufacture ViroMed Oncology Vaccine

  • Cobra Biomanufacturing will produce ViroMed’s VM206RY, a plasmid DNA treatment for tumors expressing Her2/neu. Cobrabio will manufacture ViroMed’s master cell bank and GMP-grade VM206RY for the first clinical trials, which will be held in Korea and in the U.S.

    VM206 is an anticancer vaccine targeting Her2/neu-positive breast or ovarian cancer. The compound has shown in preclinical studies to elicit an immune response to Her-2, resulting in the reduction in the growth and the recurrence rate of breast or ovarian cancer.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Should the CDC Director Resign?

Do you think the CDC chief should resign?